BB
CLVS

BB Biotech’s Clovis Oncology, Inc. CLVS Stock Holding History

BB Biotech’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-528,188
Closed -$10.1M – 32
2016
Q1 		$10.1M Hold
528,188
– – 0.4% 26
2015
Q4 		$18.5M Sell
528,188
-90,000
-15% -$5.8M 0.52% 27
2015
Q3 		$56.8M Hold
618,188
– – 1.8% 15
2015
Q2 		$54.3M Hold
618,188
– – 1.47% 21
2015
Q1 		$45.9M Hold
618,188
– – 1.37% 21
2014
Q4 		$34.6M Buy
618,188
+60,000
+11% +$3.15M 1.12% 22
2014
Q3 		$25.3M Hold
558,188
– – 1.03% 21
2014
Q2 		$23.1M Buy
558,188
+70,000
+14% +$3.61M 1.1% 19
2014
Q1 		$33.8M Hold
488,188
– – 1.74% 15
2013
Q4 		$29.4M Buy
488,188
+106,302
+28% +$5.78M 1.57% 15
2013
Q3 		$23.2M Buy
+381,886
New +$27.1M 1.26% 18

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BB Biotech's CLVS Position: Q2 2016 in Review

BB Biotech sold out of Clovis Oncology, Inc. (CLVS) in Q2 2016, closing a stake of 528,188 shares — an estimated $10.1M sold.

BB Biotech first reported a position in CLVS in Q3 2013 and held it in 11 quarters. The position peaked at $56.8M in Q3 2015. 122 funds tracked by Wall St. Rank hold CLVS as of Q2 2016.

  • BB Biotech reported no remaining Clovis Oncology, Inc. position as of Q2 2016 after selling out during the quarter.
  • BB Biotech sold 528,188 Clovis Oncology, Inc. shares in Q2 2016, an estimated $10.1M.
  • BB Biotech first reported a position in Clovis Oncology, Inc. in Q3 2013 and held it in 11 quarters.
  • BB Biotech's Clovis Oncology, Inc. position peaked at $56.8M in Q3 2015.
  • 122 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2016.

Based on BB Biotech's 13F filing for Q2 2016, filed 12 Aug 2016.